Introduction
============

Pancreatic neuroendocrine tumors (pNETs) include a heterogeneous group of tumors and account for about 3%-5% of all pancreatic malignancies, with an incidence estimated to range from 0.3 to 0.4 per 100,000 in the United States [@B1]-[@B3]. The incidence and prevalence of pNETs have increased about five-fold in the last three decades, partly due to the improvement of diagnostic standards and early detection of asymptomatic lesions [@B3]. The pNETs can be divided into functional and nonfunctional tumors. Functional tumors, such as insulinomas and gastrinomas, can secrete hormones and lead to corresponding clinical symptoms, whereas nonfunctional tumors cause non-specific symptoms, such as pain, an abdominal mass, pernicious vomiting, and anemia [@B4], [@B5].

The mainstay of treatment for pNETs is surgery. However, most patients are contraindicated for resection, because 65% of patients have unresectable or metastatic disease at the time of diagnosis [@B6]. Unresectable pNETs are associated with a poor prognosis, with a median overall survival (mOS) of 24 months [@B3]. The 10-year survival rate is only 40% and has not changed significantly over the last 30 years [@B2]. Newer chemotherapeutic agents and molecular targeted therapy have recently been developed to treat the unresectable pNETs, but their efficacy has been modest [@B7].

The genetic background of pNETs has not been fully understood. One study has revealed that there are multiple genetic mutations in nonfamilial pNETs, including mutations in multiple endocrine neoplasias type 1 (MEN1), DAXX (death domain-associated protein)/ATRX (α-thalassemia/mental retardation syndrome X-linked), and genes in the mammalian target of rapamycin (mTOR) pathway [@B8]. Interestingly, the mutations in the MEN1 and DAXX/ATRX genes are associated with a better prognosis of pNET patients in that study. Furthermore, the investigators suggest that the identification of mutations in genes in the mTOR pathway could be used to stratify pNET patients for treatment with mTOR inhibitors [@B8].

We have been interested in elucidating the genetic mechanisms for the development and progression of pNETs and believe patients\' pharmacogenetic characgteristics could be used to guide their diagnosis and treatment. Additionally, it has been well documented that there are significant differences in genetic/genomic variations for many diseases among various ethnic groups. In the present study, we analyzed the gene mutations of Chinese pNET patients. Considering that all of the published studies had focused on Caucasian and Western populations and no studies have been conducted in Chinese populations, we compared the mutations in our patients with those of the previous studies in Westerners and examined the relationship between the key gene mutations and the clinic-pathological features and prognosis of our pNET patients.

Materials and Methods
=====================

Ethics Statement
----------------

The study was reviewed and approved by the Institutional Review Board (IRB) of Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China. Informed written consent to participate in the study was obtained from each of the patients before the entry of the study.

Patient Characteristics, Tissue Samples, and Follow-Up
------------------------------------------------------

This was a retrospective study. From 2005 to 2011, 43 consecutive pNET patients underwent surgical resections of their tumors and had a definite pathological diagnosis of pNET in the Department of Surgery, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China. Six cases also had pancreatic adenocarcinoma and were excluded from the present study; therefore, 37 patients were finally enrolled in the study. All tumor specimens were formalin-fixed and paraffin-embedded. The tumors were classified into three groups according to the 2010 World Health Organization (WHO) classification criteria [@B9]. The clinic-pathological data are shown in Table [1](#T1){ref-type="table"}. Patients were followed up, and the overall survival time was analyzed.

DNA Extraction and Gene Sequencing
----------------------------------

Cellular DNA was extracted from formalin-fixed paraffin-embedded (FFPE) tumor tissues using the QIAamp DNA FFPE Tissue Kit (QIAGEN, China). DNA was extracted only from samples with more than 80% tumor cell content. Target gene amplification was accomplished using Unicorn PCR per-mix kit (Shenzhen, China); the gene sequence and data analyses were applied under the guideline of HYKGENE sequence reagents kit or operation guide (Shenzhen, China). The sequencing flux requirement by a single locus was higher than that of 300×, and the quality requirement of the single locus sequence number was higher than 100× base number accounts for more than 95% of the total length. In somatic mutation selection criteria, the sequencing depth was more than 100, which had on different reads and distribution in different positions. The SNP/somatic mutations of the candidate loci were compared with the SNP database on the HapMap to confirm whether they were reported. Finally, filters were used to remove coding-synon, eventually forming the somatic mutation data of the Chinese pNET patients.

Literature Review: Inclusion Criteria, Search Strategies, and Data Extraction
-----------------------------------------------------------------------------

In the present study, we also conducted a systemic review on pNET clinical studies. Studies were selected according to the following inclusion criteria: 1) studies must explore the genetic alterations of pNETs; and 2) studies must be published in English in a peer-reviewed journal. We performed a search of the National Center for Biotechnology Information (NCBI) PubMed database using the search terms "Pancreatic endocrine tumors OR Pancreatic neuroendocrine tumors OR pancreatic islet cell tumor OR gastrinoma OR insulinoma OR glucagonoma OR vasoactive intestinal peptide tumor OR somatostatinoma OR nfpets OR growth hormone tumor OR acth tumor OR pancreatic polypeptide tumor OR pets causing carcinoid syndrome OR pets causing hypercalcemia AND mutation". This search yielded 2278 articles published as of November 1, 2013. After manually screening the studies, we selected 178 articles for data mining, based on the aforementioned criteria. The data were extracted by two investigators independently to avoid any bias due to personal preference. When the two investigators were not in agreement, a third person was consulted to reach a final agreement regarding whether the article was suitable. The following information, if presented, was extracted and tabulated from each article: first author, year of publication, journal, genotype, gene, mutation type, chromosomal location, number of cases, number of mutation cases, population, family history, pNET type, gender, and any other important information.

Statistical Analysis
--------------------

The chi-squared test was used to analyze the categorical variables. The log-rank test for the Kaplan-Meier method and the Cox regression test were used to assess the patients\' outcomes and the prognostic factors. All statistical analyses were performed using the SPSS 17.0 software program. A two-tailed value of P\<0.05 was considered statistically significant.

Results
=======

Literature search results
-------------------------

Based on the literature search, 178 papers were included in the analysis of the mutation frequency after manually screening the full text. These reports described 551 mutations in 11 different genes (SMAD4/DPC4, KRAS, TP53, VHL, PTEN, TSC2, DAXX/ATRX, MEN1, BRAF, BRCA2 and PIK3CA). The mutations and the gene functions were summarized as a table ([Supplementary Table 1](#ST1){ref-type="supplementary-material"}).

Mutation Frequency in pNET Tissue Samples
-----------------------------------------

By using Sanger sequencing, we identified 133 somatic mutations in eight different genes in our cases (Table [2](#T2){ref-type="table"}). The somatic mutation frequency of the DAXX/ATRX, KRAS, MEN1, mTOR pathway genes (PTEN and TSC2), SMAD4/DPC, TP53 and VHL were 54.05%, 10.81%, 35.14%, 54.05%, 2.70%, 13.51%, and 40.54%, respectively.

There were some obvious differences between our findings and the results reported by Jiao et al [@B8], in which similar genes were investigated. In our study, the KRAS, TP53, mTOR pathway genes (PTEN and TSC2), and VHL genes had significantly higher mutation rates than those in their study (Table [3](#T3){ref-type="table"}). The potential reasons for these differences are not clear by may be associated with the following: 1) most of the subjects in their study were Caucasian (85%), while in our study, all of the patients were Chinese; and 2) there were only three patients with Grade 3 (poorly differentiated) tumors in their study (5%), but there were six cases (16.2%) with of poorly differentiated tumors in our study.

Gene Mutations in KRAS, TP53, TSC2, and VHL in pNET Tissue Samples
------------------------------------------------------------------

The mutation frequencies of the KRAS, TP53, TSC2, and VHL genes in our study were different from those in Caucasians, so we subjected these genes to a more detailed mutation analysis (Table [2](#T2){ref-type="table"}). We detected four cases with KRAS mutations, all of which were missense mutations. There were two G-to-A transitions and one T-to-C transition and one C-to-T transition. All of the mutations were in the GTPase domain. Fifteen of the 30 cases examined for VHL gene mutations were positive, including 23 different mutant sites, among which were 18 missense mutations, four indels, and one nonsense mutations. C-to-T transitions and C-to-A transitions were responsible for 55.6% and 27.8%, respectively, of the missense mutations. The mutations occurred mainly in the β domain and its nearby regions.

Fifteen cases were identified that had TSC2 gene mutations, among which 25 different mutant sites containing 14 missense mutations and 11 indels were found. There were two G-to-A transitions, one G-to-C, one C-to-G, and one C-to-A transition. The TSC2 mutations mainly occurred in or near the RAP-GAP domain. We detected five cases with TP53 mutations, three of which were missense mutations and two of which were indels. Two C-to-A transitions were detected in the missense mutations. One patient had an indel mutation at the 258 region, which is located at the center of the TP53 DNA binding domain (102-292 region). This patient had a higher degree of differentiation and an earlier clinical stage compared to the other patients. His overall survival time was also longer than the average of the remaining patients (45.8 vs. 26.7 months, P\<0.05). This suggested that patients with the TP53 indel mutation in the 258 region may have a lower level of malignancy and a better prognosis.

Relationships between Gene Mutations and the Clinico-pathological Characteristics of pNETs
------------------------------------------------------------------------------------------

The three most frequently mutated genes found in our study were DAXX/ATRX (54.1%), TSC2 (43.2%) and VHL (40.5%). Missense mutations were the most common type of mutation in DAXX/ATRX and VHL (comprising 82.1% and 78.3% of mutations, respectively), while in TSC2, missense and indel mutations comprised 54.2% and 45.8% of the mutations, respectively (Table [4](#T4){ref-type="table"}). The number of mutations among these well-differentiated samples are from 0 to 6 and we cutoff at the median 3, there were 27 patients have 3 or less genes occur mutations and only 9 patients in them have higher Ki-67 index or associated with the nerve vascular invasion or organ involvement. Otherwise in other 4 patients with more than 3 mutated genes all have these features (Table [5](#T5){ref-type="table"}). This difference may indicates that well-differentiated patients with mutations of multiple genes tend tumor invasion. Specifically, one patient (No. 25) had six gene mutations, with a Ki-67 index of 80%, with neurological vascular invasion and spleen metastasis. These findings suggested that the number of mutated genes may be correlated with the pNETs\' growth and progression.

The KRAS and DAXX/ATRX Gene Mutations Predict a Poor Prognosis in Patients With pNETs
-------------------------------------------------------------------------------------

We assessed whether the mutations in KRAS, TP53, mTOR pathway genes (PTEN and TSC2), VHL, SMAD4/DPC4, DAXX/ATRX, and MEN1 were associated with the patient survival. A Kaplan-Meier survival analysis was performed for the 37 pNET patients. Mutations in KRAS and DAXX/ATRX were found to be associated with a shortened survival (Figure [1](#F1){ref-type="fig"}), while mutations in TP53, mTOR pathway genes (PTEN and TSC2), VHL, SMAD4/DPC4, and MEN1 did not predict the pNET patients\' survival (Figure [2](#F2){ref-type="fig"}). To our knowledge, this is the first report that the presence of KRAS gene mutations was confirmed in pNETs, and furthermore, provides the first evidence that KRAS gene mutations may predict a poor survival.

Interestingly, the result that mutations of DAXX/ATRX were associated with a shortened survival was inconsistent with the report by Jiao et al.[@B8] Their results showed that mutations in MEN1, DAXX/ATRX, or the combination of both MEN1 and DAXX/ATRX were associated with prolonged survival relative to that of the patients whose tumors lacked these mutations. The results reported by Marinoni et al. [@B10] are in agreement with our results. In their report, the mutations found in the DAXX/ATRX genes correlated with the loss of the corresponding protein expression in pNETs, and loss of DAXX/ATRX expression was significantly correlated with both a shortened relapse-free survival and tumor-specific survival.

Discussion
==========

In the present study with 37 Chinese pNET patients, we identified 133 somatic mutations in eight different genes, including KRAS, TP53, PTEN, TSC2, VHL, SMAD4/DPC4, DAXX/ATRX, and MEN1. Compared to the results from Caucasians, there were several remarkable differences: 1) the KRAS, TP53, mTOR pathway genes (PTEN and TSC2), and VHL genes had significantly higher mutation rates in Chinese patients than in Caucasian patients; 2) the number of gene mutations was correlated with the growth and progression of well-differentiated PNETs patients; and 3) KRAS and DAXX/ATRX gene mutations were associated with a shortened survival in Chinese pNET patients.

The mutations of such genes may be involved in the development and progression of pNETs. The VHL protein contains two structural domains, called α and β. The α domain can bind to Elongin B or C, while the β domain can interact with hypoxia-inducible factor-1α (HIF-1α). Fifteen of the 30 cases that were evaluated were identified to have VHL gene mutations, and the mutations occurred mainly in or near the β domain. This may have caused VHL to fail to interact with HIF-1α, which would lead to a decrease in HIF-1α ubiquitination and degradation. As a result, the subsequent downstream genes of HIF-1α, such as VEGF, TGF-α and various cytokines, would exhibit sustained activation, which could promote tumor development and progression [@B11], [@B12].

It has been demonstrated that pNETs exhibit overexpression of VEGF, its receptor, VEGFR, and platelet-derived growth factor receptor (PDGFR) [@B13], [@B14]. Sunitinib malate, an oral tyrosine kinase inhibitor, has activity against VEGFRs, PDGFRs, stem-cell factor (KIT) receptor, glial cell line-derived neurotrophic factor, and FMS-like tyrosine kinase-3 [@B15]. Recently, several phase II and phase III trials have demonstrated that the administration of sunitinib can significantly improve the progression-free survival and overall survival, and that it shows an acceptable safety profile in patients with advanced pNETs [@B16]-[@B18].

During the process of pNET development, the receptor tyrosine kinase (RTK)-PI3K/PTEN-AKT-TSC1/2-mTOR signaling pathway plays an important role in the control of cell growth, proliferation, survival, and differentiation [@B19], [@B20]. TSC2 and TSC1 can form a dimer and inhibit the GTPase activity of Rheb, a critical activator of mTOR signaling [@B21]. TSC2 contains two structural domains: one is necessary for the binding to TSC1, but the deletion of this domain has no effect on its GAP activity; another is the RAP-GAP domain. When this domain is mutated, the GTPase activity of Rheb is enhanced, resulting in the activation of mTOR [@B22]. In our study, TSC2 mutations mainly occurred in or near the RAP-GAP domain. Everolimus is an mTOR inhibitor, and many studies have shown the efficacy and safety of everolimus in the treatment of advanced pNETs [@B23]-[@B25]. Based on these findings, the results of our study are consistent with the previous reports, and may help predict the response of pNETs to molecular targeted therapies [@B8].

Mutations in DAXX or ATRX have been detected in about 40% of pNETs. DAXX is an H3.3-specific histone chaperone, while ATRX encodes a protein that has an ADD (ATRX-DNMTT3-DNMT3L) domain at the amino-terminus and a carboxy-terminal helicase domain [@B10], [@B26]. The interaction between DAXX and ATRX is required for H3.3 incorporation at the telomeres, and ATRX, but not DAXX, could suppress the telomeric repeat-containing RNA expression. Furthermore, ATRX was also found to target CpG islands and G-rich tandem repeats, which exist close to telomeric regions [@B27]-[@B30]. In our study, the relationship between DAXX/ATRX mutations and the poor prognosis of pNET patients was inconsistent with the findings of a previous report. In that report, Jiao et al. showed that DAXX/ATRX mutations were associated with prolonged survival in pNET patients. In contrast, Marinoni et al. showed that the loss of DAXX/ATRX expression caused by a DAXX/ATRX gene mutation was significantly correlated with both a shortened relapse-free and tumor-specific survival. The reasons for these differences may include the following: 1) The DAXX/ATRX mutation rate in our study was higher than that in the other studies; 2) The patients in our study were all Chinese, while those in the other studies were mostly Caucasian; and 3) The mutated regions of DAXX/ATRX in our study were different from those in the other studies.

KRAS, a member of the rat sarcoma viral oncogene homolog (RAS) proto-oncogene family, is a key protein in the EGFR pathway, and plays an important role in the activation of various downstream proteins, including Raf, MEK and ERK [@B31]. The mutant status of KRAS may inhibit GTP enzymatic activity, resulting in sustained activation of the EGRF signaling pathway. Codons 12, 13, and 61 are the most common mutation sites in KRAS [@B32], [@B33]. The mutation rate of KRAS in pancreatic cancer is about 90%, and there is a major region of mutation in codon 12. However, the KRAS mutation rate in pNETs has rarely been reported. In our study, the mutation rate of KRAS was 10.81%, while there were no KRAS mutations reported by Jiao et al. The KARS mutations in our study were found in codons 7, 12, and 18. Interestingly, our study suggests that the presence of a KRAS gene mutation may predict a poorer survival. This was a novel finding, but needs to be further analyzed in a larger number of patients.

In conclusion, the significance of our study is the first to report the gene mutations of pNETs in Chinese patients. Our data indicated that DAXX/ATRX and KRAS gene mutations were correlated with a poor prognosis of pNET patients, and the patients bearing a larger number of gene mutations had a worse prognosis. The limitation of this study may be associated with the small sample size and the sequence methods; thus, future studies enrolling a larger number of pNET patients should be performed, and whole exome sequencing should be conducted to further explore the role of newly identified gene mutations in pNET development and progression.
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======================
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![The Kaplan-Meier curves of the overall survival of pNET patients, stratified by the status of gene mutations. A: DAXX/ATRX; B: KRAS. Mutations in DAXX/ATRX and KRAS were found to be associated with a shortened survival (n=37; all p\<0.05).](ijbsv10p0957g001){#F1}

![The Kaplan-Meier curves of the overall survival of pNET patients, stratified by the status of gene mutations. A: TP53; B: PTEN; C: TSC2; D: VHL; E: SMAD4/DPC4; and F: MEN1. These mutations analyzed were not associated with survivals of the pNET patients (n=37; all p\>0.05).](ijbsv10p0957g002){#F2}

###### 

Characteristics of the 37 patients with pNETs from Ruijin Hospital.

  Sample   Age   Gender   Function     WHO classification   TNM(A7)   Ki-67
  -------- ----- -------- ------------ -------------------- --------- -------
  pNET1    41    Male     NF           G1                   Ib        ≤2%
  pNET2    37    Female   NF           G1                   Ib        ≤2%
  pNET3    54    Male     NF           G2                   Ib        ≤2%
  pNET4    18    Male     NF           G2                   IV        3-20%
  pNET6    61    Male     NF           G1                   Ib        ≤2%
  pNET7    58    Female   NF           G1                   IIb       ≤2%
  pNET9    32    Female   Insulinoma   G1                   Ia        ≤2%
  pNET10   66    Male     NF           G1                   IIa       ≤2%
  pNET11   64    Female   NF           G1                   Ib        ≤2%
  pNET13   51    Female   NF           G1                   Ia        ≤2%
  pNET14   48    Male     NF           G1                   IIb       ≤2%
  pNET15   47    Male     NF           G1                   Ib        ≤2%
  pNET16   48    Male     NF           G1                   Ib        ≤2%
  pNET17   61    Female   NF           G1                   Ib        ≤2%
  pNET18   47    Male     NF           G3                   IIb       \>20%
  pNET20   38    Female   NF           G2                   Ia        ≤2%
  pNET21   65    Female   Insulinoma   G2                   IV        3-20%
  pNET22   67    Female   NF           G2                   Ia        ≤2%
  pNET23   54    Male     NF           G2                   Ia        ≤2%
  pNET24   62    Female   NF           G1                   Ib        ≤2%
  pNET25   47    Male     NF           G3                   IIa       \>20%
  pNET28   57    Female   NF           G1                   Ib        ≤2%
  pNET29   61    Female   Insulinoma   G1                   Ia        ≤2%
  pNET30   61    Female   NF           G1                   Ib        ≤2%
  pNET31   45    Male     NF           G1                   Ia        ≤2%
  pNET32   55    Female   NF           G1                   Ia        ≤2%
  pNET33   59    Female   Insulinoma   G1                   Ia        ≤2%
  pNET34   47    Male     NF           G2                   IIa       ≤2%
  pNET35   62    Female   NF           G1                   Ia        ≤2%
  pNET36   67    Female   NF           G1                   Ib        ≤2%
  pNET37   72    Male     NF           G1                   Ib        ≤2%
  pNET38   47    Female   NF           G2                   Ib        3-20%
  pNET39   57    Male     NF           G3                   IIa       \>20%
  pNET40   37    Male     NF           G3                   IIb       \>20%
  pNET41   64    Male     NF           G3                   IIa       \>20%
  pNET42   61    Female   NF           G3                   IV        \>20%
  pNET43   35    Female   NF           G2                   Ib        3-20%

###### 

The mutations in SMAD4/DPC4. KRAS, TP53, VHL, PTEN, TSC2, DAXX, ATRX, and MEN1 in pNETs.

  Sample   Gene         Nucleotide (genomic)      Amino acid change      Mutation type
  -------- ------------ ------------------------- ---------------------- ---------------
  pNET4    ATRX         chrx:76778854             CAG(Q)\>CCG(P)         missense
           ATRX         chrx:76907608             AGA(R)\>ATA(I)         missense
           ATRX         chrx:76814262             GCT(A)\>ACT(T)         missense
           ATRX         chrx:76814186             CGC(R)\>CAC(H)         missense
  pNET9    ATRX         chrx:76907836-76907837                           indel
  pNET15   ATRX         chrx:76907741             Gly(GGA)-\>Arg(AGA)    missense
  pNET17   ATRX         chrx:76907744             Pro(CCT)-\>Ser(TCT)    missense
  pNET25   ATRX         chrx:76874303             CTC(L)\>GTC(V)         missense
  pNET28   ATRX         chrx:76907645             CGT(R)\>GGT(G)         missense
  pNET31   ATRX         chrx:76778855             CAG(Q)\>TAG(Stop)      nonsense
  pNET34   ATRX         chrx:76874303             CTC(L)\>GTC(V)         missense
  pNET37   ATRX         chrx:76778844             AAA(K)\>AAT(N)         missense
  pNET40   ATRX         chrx:76939403             CCT(P)\>GCT(A)         missense
           ATRX         chrx:76907612             TTG(L)\>ATG(M)         missense
           ATRX         chrx:76907660             GAA(E)\>AAA(K)         missense
  pNET41   ATRX         chrx:76907663             GAG(E)\>CAG(Q)         missense
           ATRX         chrx:76907840             AAT(N)\>TAT(Y)         missense
  pNET42   ATRX         chrx:76909619             AAG(K)\>AGG(R)         missense
           ATRX         chrx:76907840             AAT(N)\>TAT(Y)         missense
  pNET43   ATRX         chrx:76907660             GAA(E)\>AAA(K)         missense
  pNET1    DAXX         chr6:33287895             Glu(GAA)-\>Gly(GGA)    missense
  pNET3    DAXX         chr6:33288158             Glu(GAG)-\>Val(GTG)    missense
  pNET4    DAXX         chr6:33287895             Glu(GAA)-\>Gly(GGA)    missense
  pNET6    DAXX         chr6:33287869             Glu(GAA)-\>Lys(AAA)    missense
  pNET15   DAXX         chr6:33289268             Ala(GCC)-\>Val(GTC)    missense
  pNET20   DAXX         chr6:33289256-33289256                           indel
  pNET22   DAXX         chr6:33289256-33289256                           indel
  pNET25   DAXX         chr6:33286925             TCC(S)\>TTC(F)         missense
  pNET29   DAXX         chr6:33288170             L-Stop 413             nonsense
  pNET30   DAXX         chr6:33287844             ATG(M)\>AGG(R)         missense
  pNET31   DAXX         chr6:33287902             GAG(E)\>CAG(Q)         missense
           DAXX         chr6:33287844             ATG(M)\>AGG(R)         missense
  pNET15   KRAS         chr12:25398299            Val(GTG)-\>Ala(GCG)    missense
  pNET25   KRAS         chr12:25398284            rs121913529            missense
                                                  Gly(GGT)-\>Asp(GAT)    
  pNET31   KRAS         chr12:25398266            Ala(GCC)-\>Val(GTC)    missense
  pNET40   KRAS         chr12:25398284            rs121913529            missense
                                                  Gly(GGT)-\>Asp(GAT)    
  pNET1    MEN1         chr11:64577464            Val(GTG)-\>Leu(TTG)    missense
           MEN1         chr11:64577355            T-\>I 76               missense
  pNET3    MEN1         chr11:64577526            Val(GTG)-\>Glu(GAG)    missense
  pNET4    MEN1         chr11:64574502            Pro(CCA)-\>Leu(CTA)    missense
           MEN1         chr11:64577391            CAG(Q)\>CGG(R)         missense
           MEN1         chr11:64577182            TTC(F)\>CTC(L)         missense
  pNET9    MEN1         chr11:64577397            Thr(ACC)-\>Ile(ATC)    missense
  pNET13   MEN1         chr11:64574514            Gly(GGC)-\>Asp(GAC)    missense
  pNET14   MEN1         chr11:64577307            R-\>H 92               missense
           MEN1         chr11:64577397            Thr(ACC)-\>Ile(ATC)    missense
  pNET15   MEN1         chr11:64577185            Y-\>H 133              missense
  pNET17   MEN1         chr11:64574502            Pro(CCA)-\>Leu(CTA)    missense
  pNET30   MEN1         chr11:64574565            CCC(P)\>CTC(L)         missense
  pNET33   MEN1         chr11:64577389            CCC(P)\>ACC(T)         missense
                                                  CCC(P)\>TCC(S)         missense
  pNET34   MEN1         chr11:64577316            Leu(CTC)-\>Arg(CGC)    missense
           MEN1         chr11:64577389            CCC(P)\>ACC(T)         missense
                                                  CCC(P)\>TCC(S)         
  pNET35   MEN1         chr11:64574671            Tyr(TAT)-\>Stop(TAG)   nonsense
  pNET38   MEN1         chr11:64574502            Pro(CCA)-\>Leu(CTA)    missense
  pNET3    TP53         chr17:7579424             Ala(GCC)-\>Asp(GAC)    missense
  pNET25   TP53         chr17:7579387             Q-\>H 100              missense
  pNET36   TP53         chr17:7577509-7577509                            indel
  pNET37   TP53         chr17:7579293-7579294                            indel
  pNET41   TP53         chr17:7578481             ACA(T)\>AAA(K)         missense
  pNET3    PTEN         chr10:89720826            Asp(GAC)-\>Ala(GCC)    missense
  pNET18   PTEN         chr10:89720870            Phe(TTT)-\>Val(GTT)    missense
  pNET21   PTEN         chr10:89720870            Phe(TTT)-\>Val(GTT)    missense
  pNET24   PTEN         chr10:89720826            Asp(GAC)-\>Ala(GCC)    missense
  pNET25   PTEN         chr10:89720853            CGA(R)\>CAA(Q)         missense
  pNET32   PTEN         chr10:89720870            Phe(TTT)-\>Val(GTT)    missense
  pNET34   PTEN         chr10:89685307            TAC(Y)\>CAC(H)         missense
           PTEN         chr10:89720816-89720817   rs121913291            indel
  pNET22   SMAD4/DPC4   chr18:48593423            Lys(AAA)-\>Gln(CAA)    missense
  pNET1    TSC2         chr16:2134968             Leu(CTC)-\>Val(GTC)    missense
  pNET4    TSC2         chr16:2130258             GCG(A)\>ACG(T)         missense
  pNET7    TSC2         chr16:2134973-2134974     rs137854017            indel
  pNET10   TSC2         chr16:2134973-2134974     rs137854017            indel
  pNET15   TSC2         chr16:2134994             D-\>E 151              missense
           TSC2         chr16:2135013             L-\>M 1519             missense
  pNET16   TSC2         chr16:2134994             D-\>E 151              missense
           TSC2         chr16:2135013             L-\>M 1519             missense
           TSC2         chr16:2136843             G-\>S 1654             missense
  pNET20   TSC2         chr16:2136843             G-\>S 1654             missense
  pNET24   TSC2         chr16:2134992             D-\>N 1512             missense
           TSC2         chr16:2136873-2136873     rs137854005            indel
  pNET25   TSC2         chr16:2130168-2130169     rs137854314            indel
  pNET28   TSC2         chr16:2134961-2134962     rs137854160            indel
  pNET29   TSC2         chr16:2130168-2130169     rs137854314            indel
  pNET30   TSC2         chr16:2134329             CGG(R)\>CAG(Q)         missense
  pNET31   TSC2         chr16:2134328             rs45517328 1369        missense
           TSC2         chr16:2134391             GAG(E)\>CAG(Q)         missense
  pNET33   TSC2         chr16:2134961-2134962     rs137854160            indel
           TSC2         chr16:2130259             rs45448801             missense
                                                  GCG(A)\>GAG(E)         
  pNET34   TSC2         chr16:2134961-2134962     rs137854160            indel
  pNET35   TSC2         chr16:2134961-2134962     rs137854160            indel
           TSC2         chr16:2130168-2130169     rs137854314            indel
           TSC2         chr16:2130266-2130266     rs137854340            indel
  pNET1    VHL          chr3:10183775             Arg(CGC)-\>Cys(TGC)    missense
           VHL          chr3:10188212             F-\>I 119              missense
           VHL          chr3:10188218             D-\>H 121              missense
           VHL          chr3:10183734             Ser(TCG)-\>Leu(TTG)    missense
  pNET3    VHL          chr3:10183737             Arg(CGC)-\>His(CAC)    missense
           VHL          chr3:10188304-10188305                           indel
  pNET7    VHL          chr3:10191563             Glu(GAA)-\>Lys(AAA)    missense
  pNET10   VHL          chr3:10183841             Gly(GGC)-\>Ser(AGC)    missense
  pNET13   VHL          chr3:10188307-10188308    rs5030624              indel
  pNET14   VHL          chr3:10183736             Arg(CGC)-\>Cys (TGC)   missense
           VHL          chr3:10183734             Ser(TCG)-\>Leu(TTG)    missense
  pNET15   VHL          chr3:10183736             Arg(CGC)-\>Cys (TGC)   missense
  pNET17   VHL          chr3:10183826             Pro(CCA)-\>Ser(TCA)    missense
  pNET20   VHL          chr3:10183734             Ser(TCG)-\>Leu(TTG)    missense
           VHL          chr3:10188304-10188305                           indel
  pNET22   VHL          chr3:10183734             Ser(TCG)-\>Leu(TTG)    missense
  pNET25   VHL          chr3:10183736             Arg(CGC)-\>Cys (TGC)   missense
           VHL          chr3:10183682             Glu(GAG)-\>Stop(TAG)   nonsense
  pNET28   VHL          chr3:10183704             CGG(R)\>CAG(Q)         missense
  pNET33   VHL          chr3:10183802             Phe(TTC)-\>Leu(CTC)    missense
  pNET34   VHL          chr3:10188304-10188305                           indel
  pNET38   VHL          chr3:10183809             GGC(G)\>GAC(D)         missense
           VHL          chr3:10188230             CAC(H)\>TAC(Y)         missense

###### 

Comparison of the most commonly mutated genes in pNETs between Chinese and Caucasians.

  Genes                  pNETs (Chinese)   pNETs (Caucasian)^a^
  ---------------------- ----------------- ----------------------
  KRAS                   10.81%            0%
  TP53                   13.51%            3%
  mTOR (PTEN and TSC2)   54.05%            15%
  VHL                    40.54%            0%
  SMAD4/DPC4             2.70%             0%
  DAXX/ATRX              54.05%            43%
  MEN1                   35.14%            44%

^a^ The data are from Science 2011;331:1199-203.

###### 

All gene mutations identified in the 37 Chinese pNETs patients.

  Sample   SMAD4/DPC4   KRAS       TP53       VHL                  PTEN              TSC2              DAXX/ATRX            MEN1
  -------- ------------ ---------- ---------- -------------------- ----------------- ----------------- -------------------- ----------
  pNET1                                       missense                               missense          missense             missense
  pNET2                                                                                                                     
  pNET3                            missense   missense/ indel      indel                               missense             missense
  pNET4                                                                              missense          missense             missense
  pNET6                                                                                                missense             
  pNET7                                       missense                               Indel                                  
  pNET9                                                                                                indel                missense
  pNET10                                      missense                               Indel                                  
  pNET11                                                                                                                    
  pNET13                                      indel                                                                         missense
  pNET14                                      missense                                                                      missense
  pNET15                missense              missense                               missense          missense             missense
  pNET16                                                                             missense                               
  pNET17                                      missense                                                 missense             missense
  pNET18                                                           missense                                                 
  pNET20                                      missense/ indel                        missense          indel                
  pNET21                                                           missense                                                 
  pNET22   Missense                           missense                                                 indel                
  pNET23                                                                                                                    
  pNET24                                                           missense          missense/ indel                        
  pNET25                missense   missense   missense/ nonsense   missense          indel             missense             
  pNET28                                      missense                               indel             missense             
  pNET29                                                                             indel             nonsense             
  pNET30                                                                             missense          missense             missense
  pNET31                missense                                                     missense          missense/ nonsense   
  pNET32                                                           missense                                                 
  pNET33                                      missense                               indel                                  missense
  pNET34                                      indel                missense/ indel   indel             missense             missense
  pNET35                                                                             indel                                  nonsense
  pNET36                           indel                                                                                    
  pNET37                           indel                                                               missense             
  pNET38                                      missense                                                                      missense
  pNET39                                                                                                                    
  pNET40                missense                                                                       missense             
  pNET41                           missense                                                            missense             
  pNET42                                                                                               missense             
  pNET43                                                                                               missense             

###### 

The relationship between the number of mutated genes and the Ki-67 index or TNM stage of well-differentiated pNETs patients.

              Ki-67 index or TNM stage        
  ------ ---- -------------------------- ---- -------
  ≤ 3    27   9                          18   0.012
  \> 3   4    4                          0    

[^1]: \*Equal contribution.
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